ST. LOUIS, June 6 /PRNewswire/ -- Lee Biosolutions, Inc, a worldwide supplier for porcine liver esterase has announced it has increased its capacity to an industrial scale of over 150 million units per batch size.
Lee Biosolutions supplies Porcine Liver Esterase and other stable high purity enzymes and related proteins to major diagnostic companies used in urine tests as an indicator of blood or urine infection. Porcine liver esterase is also used on a large commercial scale as a biocatalyst in the resolution of mixtures of chiral esters by hydrolysis to produce optically active carboxylic acids.
Lee Biosolutions growth for porcine liver esterase is attributed to meeting stringent customer specifications while maintaining consistent high quality products that out perform other manufacturers on the market. Lee Biosolutions scientific team operates with built-in flexibility, is able to respond in a timely manner and has some of the best scientists working in this industry.
According to Lee Biosolutions President Burton Lee, porcine liver esterase demand has increased significantly over the past 12 months. "We operate with one ear constantly tuned to the diagnostic manufacturing and pharmaceutical community," Lee said. "This helps us stay on top of the latest research being conducted on hydrolase enzymes such as porcine liver esterase and gives us the information we need to stay ahead of their demands."
Lee Biosolutions is a leader in the biomarker industry, providing quality products such as http://www.leebio.com/esterase-porcine-P122 (porcine liver esterase) to clinical labs and researchers around the world, developing tomorrow's cures. For more information on porcine esterase and our capabilities go to www.leebio.com or contact:
This release was issued through WebWire(R). For more information visit http://www.webwire.com.
CONTACT: Burton Lee, President, Lee Biosolutions, Inc, +1-314-968-1091,
info@leebio.com
Web site: http://www.leebio.com/
